The targeted drug release induced DNA damage in the tumor cells, activated the cGAS-STING pathway, and increased the infiltration of DCs and CD8+ T cells in the TIME, resulting in enhanced anti-tumor immune response [66]. The gene discussed is STING1; the disease is neoplasm.